Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAPEO.L Regulatory News (APEO)

  • There is currently no data for APEO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share Buyback Programme

25 Jan 2024 07:00

RNS Number : 8134A
abrdn Private Equity Opp Trst plc
25 January 2024
 

 

25 January 2024

 

abrdn Private Equity Opportunities Trust plc

Legal Entity Identifier (LEI): 2138004MK7VPTZ99EV13

 

Share Buyback Programme

 

The Board of abrdn Private Equity Opportunities Trust plc ("APEO" or the "Company") is committed to ensuring that the Company is run in the best interests of its shareholders. As part of its duties in fulfilling that commitment, the Board and the Manager closely monitor the performance and valuation metrics relating to the underlying portfolio, as well as the evolution of the Company's share price, market capitalisation, discount to net asset value ("NAV") and shareholder register.

 

During the last 18 months, like many of its peers, APEO's share price has diverged materially from its NAV, resulting in the Company's shares trading at a material discount, in excess of the long-term average (which was 22.3% over the 10 years to 30 September 2023). During the Company's 22-year history, the share price discount to NAV has only been wider during the Global Financial Crisis and the onset of the Global Pandemic.

 

It is the Board's view that APEO's current share price presents an exceptional investment opportunity for the Company. Notably, APEO has in recent months proactively undertaken a series of partial secondary sales of its co-investment in Action for portfolio construction reasons. All of these disposals have been achieved at 100% of the most recent quarterly valuation of that asset. Furthermore, the underlying portfolio company exits from APEO's fund investments during 2023 have, on average, been transacted at sale valuations in excess of the unrealised valuation two quarters prior.

 

In accordance with the approval provided by shareholders at the AGM in March 2023, the Company has the power to buy back up to 8,056,569 of the Company's shares. The authority expires at the AGM in March 2024, when similar authority will be requested from the Company's shareholders. The Board believes that any decision to buy back APEO's shares must always be balanced against considerations such as the Company's balance sheet position, level of outstanding commitments and cashflow forecasts. Furthermore, longer term considerations, such as increasing APEO's exposure to direct co-investment, which typically require full cash funding upfront, and the Company's relatively concentrated shareholder base, must also be considered.

In weighing up the circumstances and considerations set out above, the Board has decided to use a portion of the ?34.6 million of proceeds realised from the most recent sale of APEO's direct co-investment in Action to commence a buyback programme.

 

The ability to recycle a significant portion of the Action proceeds, realised at 100% of its 30 June 2023 valuation, into buying APEO shares at a significant discount to NAV, is a compelling use of the Company's capital at this time and provides immediate NAV accretion to APEO's shareholders. It also highlights in the clearest terms the disconnect between APEO's current share price and the valuation of its underlying portfolio.

 

Going forward, the Board will continue to monitor the evolution of the share price and, in the event of further sizeable distributions from the portfolio, may look to extend the programme. The Board also notes that, since 2016, the Company has paid shareholders an enhanced dividend on a quarterly basis, which is effectively a regular return of capital to shareholders at NAV. For the avoidance of doubt, the Board intends to continue this policy going forward, with the aim of maintaining the value of the dividend in line with inflation.

 

 

For further information please contact:

 

Alan Gauld

Lead Portfolio Manager, abrdn Capital Partners LLP

Tel: 0131 528 4424

 

Paul Evitt

Abrdn Holdings Limited, Company Secretary

Tel: 0131 372 9371

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSBIMATMTITBJI
Date   Source Headline
9th Jun 20237:00 amRNSNotice of Results
17th May 202311:51 amRNSHolding(s) in Company
17th May 20237:00 amRNSEstimate NAV at 30 April 2023
25th Apr 202311:52 amRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSEstimated NAV at 31 March 2023
11th Apr 202311:23 amRNSQuarterly disclosure
22nd Mar 20231:41 pmRNSResult of AGM
16th Mar 20237:00 amRNSEstimated NAV at 28 February 2023
9th Mar 20237:00 amRNSFirst Interim Dividend
14th Feb 20237:00 amRNSEstimated NAV at 31 January 2023
10th Feb 20238:57 amRNSDoc re. Annual Financial Report
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 202311:38 amRNSDirector/PDMR Shareholding
31st Jan 202310:49 amRNSAnnual Financial Report
31st Jan 20237:00 amRNSAnnual Financial Report
18th Jan 20232:10 pmRNSNotice of Results
18th Jan 20237:00 amRNSEstimated NAV at 31 December 2022
9th Jan 20238:51 amRNSQuarterly disclosure
15th Dec 20227:00 amRNSEstimated NAV at 30 November 2022
13th Dec 20223:18 pmRNSFourth Interim Dividend Announcement
28th Nov 20227:01 amRNSCompany Secretary - Change of Name
21st Nov 20224:36 pmRNSPrice Monitoring Extension
14th Nov 20227:00 amRNSEstimated NAV at 31 October 2022
2nd Nov 20222:13 pmRNSDirector/PDMR Shareholding
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:36 pmRNSPrice Monitoring Extension
28th Oct 20229:42 amRNSEdison update on abrdn Private Equity Opp Trst
24th Oct 20224:41 pmRNSSecond Price Monitoring Extn
24th Oct 20224:36 pmRNSPrice Monitoring Extension
14th Oct 20227:00 amRNSEstimated NAV at 30 September 2022
10th Oct 20227:00 amRNSIncrease of Loan Facility
7th Oct 202210:33 amRNSQuarterly disclosure
16th Sep 20224:35 pmRNSPrice Monitoring Extension
15th Sep 20227:00 amRNSEstimated NAV at 31 August 2022
9th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20224:36 pmRNSResearch from QuotedData
8th Sep 202211:21 amRNSDirector/PDMR Shareholding
8th Sep 202210:11 amRNSDirector/PDMR Shareholding
8th Sep 20227:00 amRNSThird Interim Dividend
12th Aug 20227:00 amRNSEstimated NAV at 31 July 2022
10th Aug 20225:49 pmRNSDirector/PDMR Shareholding
9th Aug 20227:00 amRNSEdison issues review on Abrdn Private Equity Opp.
21st Jul 20224:35 pmRNSPrice Monitoring Extension
14th Jul 202210:26 amRNSDoc re. Half Yearly Report
14th Jul 20227:00 amRNSEstimated NAV at 30 June 2022
5th Jul 20222:18 pmRNSQuarterly disclosure
30th Jun 20224:36 pmRNSPrice Monitoring Extension
30th Jun 20227:00 amRNSHalf-year Report
16th Jun 20227:00 amRNSEstimated NAV at 31 May 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.